Clinical Trial Update: Safety Study of Viaskin Peanut to Treat Peanut Allergy [Phase 3]

View source ↗

Summary

Phase 3 safety study of Viaskin Peanut for peanut allergy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED